Pasithea Therapeutics Net Worth
Pasithea Therapeutics Net Worth Breakdown | KTTAW |
Pasithea Therapeutics Net Worth Analysis
Pasithea Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Pasithea Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Pasithea Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Pasithea Therapeutics' net worth analysis. One common approach is to calculate Pasithea Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Pasithea Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Pasithea Therapeutics' net worth. This approach calculates the present value of Pasithea Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Pasithea Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Pasithea Therapeutics' net worth. This involves comparing Pasithea Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Pasithea Therapeutics' net worth relative to its peers.
To determine if Pasithea Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Pasithea Therapeutics' net worth research are outlined below:
Pasithea Therapeutics is not yet fully synchronised with the market data | |
Pasithea Therapeutics is way too risky over 90 days horizon | |
Pasithea Therapeutics has some characteristics of a very speculative penny stock | |
Pasithea Therapeutics appears to be risky and price may revert if volatility continues | |
Pasithea Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
Net Loss for the year was (13.9 M) with profit before overhead, payroll, taxes, and interest of 0. | |
Pasithea Therapeutics Corp has accumulated about 568.98 K in cash with (13.92 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.07, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pasithea Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pasithea Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Pasithea Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Pasithea Therapeutics Earnings per Share Projection vs Actual
Pasithea Therapeutics Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Pasithea Therapeutics stock to make a market-neutral strategy. Peer analysis of Pasithea Therapeutics could also be used in its relative valuation, which is a method of valuing Pasithea Therapeutics by comparing valuation metrics with similar companies.
Risk & Return | Correlation |
Pasithea Therapeutics Corporate Management
Stanley Gloss | Chief Officer | Profile | |
MD BA | Ex CoFounder | Profile | |
Tiago Marques | CEO Director | Profile | |
Daniel Schneiderman | Chief Officer | Profile | |
Graeme Currie | Chief Officer | Profile |
Additional Tools for Pasithea Stock Analysis
When running Pasithea Therapeutics' price analysis, check to measure Pasithea Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pasithea Therapeutics is operating at the current time. Most of Pasithea Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pasithea Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pasithea Therapeutics' price. Additionally, you may evaluate how the addition of Pasithea Therapeutics to your portfolios can decrease your overall portfolio volatility.